The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors

被引:1
|
作者
Pavel, Marianne [1 ]
Dromain, Clarisse [2 ]
Ronot, Maxime [3 ]
Schaefer, Niklaus [2 ]
Mandair, Dalvinder [4 ]
Gueguen, Delphine [5 ]
Elvira, David [5 ]
Jegou, Simon [6 ]
Balazard, Felix [6 ]
Dehaene, Olivier [6 ]
Schutte, Kathryn [6 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, Erlangen, Germany
[2] Lausanne Univ Hosp, Lausanne, Switzerland
[3] Beaujon Hosp, Clichy, France
[4] Royal Free Hosp, London, England
[5] Ipsen, Boulogne Billancourt, France
[6] Owkin, Paris, France
关键词
artificial intelligence; deep learning; neuroendocrine tumors; progression-free survival; RECIST; CONSENSUS GUIDELINES; CLINICAL UTILITY; CHROMOGRANIN-A; DIAGNOSIS; METASTASES; MANAGEMENT; RADIOMICS; RECIST;
D O I
10.2217/fon-2022-1136
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Plain language summary - The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumorsNeuroendocrine tumors (NET) are slow-growing cancers. How well cancers respond to treatment is usually measured using 'Response Evaluation Criteria in Solid Tumors (RECIST)', which is based on measuring the size of tumors. RECIST is not well suited for assessing NETs as these tumors often grow slowly and rarely shrink significantly, so it is difficult to tell whether a treatment has any effect. A better way of measuring how well NETs are responding to treatment is needed, to ensure that patients receive the right treatment as early as possible.The RAISE project aimed to use a type of artificial intelligence (AI) called 'deep learning' to examine images of NETs, taken from patients in a clinical trial of treatment with lanreotide, to help predict how they might respond to treatment. These images were analyzed by the deep learning AI to see if there are any features of tumors, other than shape or size, that may help to predict response to treatment.The project showed that this technology can detect features in images of NETs, other than the shape and size of tumors, that are useful for predicting how well a treatment might work for an individual patient. However, this technology could not improve prediction of how well a treatment would work at an earlier stage compared with other currently used indicators.Overall, further research and work is needed to improve this technology. However, these results show that deep learning may have the potential to improve prediction of treatment response in patients with NETs. Aim: The RAISE project assessed whether deep learning could improve early progression-free survival (PFS) prediction in patients with neuroendocrine tumors. Patients & methods: Deep learning models extracted features from CT scans from patients in CLARINET (NCT00353496) (n = 138/204). A Cox model assessed PFS prediction when combining deep learning with the sum of longest diameter ratio (SLDr) and logarithmically transformed CgA concentration (logCgA), versus SLDr and logCgA alone. Results: Deep learning models extracted features other than lesion shape to predict PFS at week 72. No increase in performance was achieved with deep learning versus SLDr and logCgA models alone. Conclusion: Deep learning models extracted relevant features to predict PFS, but did not improve early prediction based on SLDr and logCgA.
引用
收藏
页码:2185 / 2199
页数:15
相关论文
共 50 条
  • [11] Progression-Free Survival in Neuroendocrine Tumors: Preferred End Point, But How Should It Be Defined?
    Riechelmann, Rachel P.
    Rego, Juliana
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (20) : 3835 - 3836
  • [12] Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors
    Pusceddu, Sara
    Prinzi, Natalie
    Tafuto, Salvatore
    Ibrahim, Toni
    Filice, Angelina
    Brizzi, Maria Pia
    Panzuto, Francesco
    Baldari, Sergio
    Grana, Chiara M.
    Campana, Davide
    Davi, Maria Vittoria
    Giuffrida, Dario
    Zatelli, Maria Chiara
    Partelli, Stefano
    Razzore, Paola
    Marconcini, Riccardo
    Massironi, Sara
    Gelsomino, Fabio
    Faggiano, Antongiulio
    Giannetta, Elisa
    Bajetta, Emilio
    Grimaldi, Franco
    Cives, Mauro
    Cirillo, Fernando
    Perfetti, Vittorio
    Corti, Francesca
    Ricci, Claudio
    Giacomelli, Luca
    Porcu, Luca
    Di Maio, Massimo
    Seregni, Ettore
    Maccauro, Marco
    Lastoria, Secondo
    Bongiovanni, Alberto
    Versari, Annibale
    Persano, Irene
    Rinzivillo, Maria
    Pignata, Salvatore Antonio
    Rocca, Paola Anna
    Lamberti, Giuseppe
    Cingarlini, Sara
    Puliafito, Ivana
    Ambrosio, Maria Rosaria
    Zanata, Isabella
    Bracigliano, Alessandra
    Severi, Stefano
    Spada, Francesca
    Andreasi, Valentina
    Modica, Roberta
    Scalorbi, Federica
    JAMA NETWORK OPEN, 2022, 5 (02)
  • [13] Development of a nomogram to predict the progression-free survival in lung cancer patients
    Tafenzi, H. A.
    Choulli, F.
    Baladi, A.
    El Fadli, M.
    Essadi, I.
    Belbaraka, R.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S155 - S155
  • [14] Progression-Free Survival (PFS) as a Primary Endpoint for Clinical Studies in Advanced Neuroendocrine Tumors (NETs)
    Singh, S.
    Law, C.
    NEUROENDOCRINOLOGY, 2010, 92 (01) : 59 - 59
  • [15] Association of Progression-Free Survival With Overall Survival in Patients With Neuroendocrine Tumor Treated With Somatostatin Analogs
    Ter-Minassian, Monica
    Brooks, Nichole V.
    Brais, Lauren K.
    Chan, Jennifer A.
    Christiani, David C.
    Lin, Xihong
    Gabriel, Sylvie
    Dinet, Jerome
    Kulke, Matthew H.
    PANCREAS, 2016, 45 (03) : 483 - 483
  • [16] A machine learning approach applied to gynecological ultrasound to predict progression-free survival in ovarian cancer patients
    Francesca Arezzo
    Gennaro Cormio
    Daniele La Forgia
    Carla Mariaflavia Santarsiero
    Michele Mongelli
    Claudio Lombardi
    Gerardo Cazzato
    Ettore Cicinelli
    Vera Loizzi
    Archives of Gynecology and Obstetrics, 2022, 306 : 2143 - 2154
  • [17] A nomogram to predict the progression-free survival of clival chordoma
    Zhai, Yixuan
    Bai, Jiwei
    Li, Mingxuan
    Wang, Shuai
    Li, Chuzhong
    Wei, Xinting
    Zhang, Yazhuo
    JOURNAL OF NEUROSURGERY, 2021, 134 (01) : 144 - 152
  • [18] Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial
    Shah, M. H.
    Lombard-Bohas, C.
    Ito, T.
    Wolin, E. M.
    Van Cutsem, E.
    Sachs, C.
    Winkler, R. E.
    Lincy, J.
    Hobday, T. J.
    Yao, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [19] A MACHINE LEARNING APPROACH APPLIED TO GYNECOLOGICAL ULTRASOUND TO PREDICT PROGRESSION-FREE SURVIVAL IN OVARIAN CANCER PATIENTS
    Arezzo, F.
    Loizzi, V.
    Cazzato, G.
    Lombardi, C.
    Venerito, V.
    Cicinelli, E.
    Cormio, G.
    Santarsiero, C. M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A66 - A66
  • [20] A machine learning approach applied to gynecological ultrasound to predict progression-free survival in ovarian cancer patients
    Arezzo, Francesca
    Cormio, Gennaro
    La Forgia, Daniele
    Santarsiero, Carla Mariaflavia
    Mongelli, Michele
    Lombardi, Claudio
    Cazzato, Gerardo
    Cicinelli, Ettore
    Loizzi, Vera
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2022, 306 (06) : 2143 - 2154